CA
NZ
UK
AU
IND
US
BridgeBio Pharma (Nasdaq:BBIO) shares closed at $80.09, down $2.05, or 2.50%, on volume of roughly 2.13 million shares. The dip is noise against the trend: the stock has gained about 76% over 12 months, sits inside a 52-week range of $42.09 to $93.42, and …
Bristol Myers Squibb (NYSE:BMY) lifted its 2026 outlook sharply on 30 July. Full-year revenue guidance moved to $49.0–$50.0 billion from the $46.0–$47.5 billion set in April, and non-GAAPEarnings Per Shareto $6.75–$7.00 from $6.05–$6.35. Second-quarter revenue reached $13.0 billion, up 6% as reported and 5% …
Corcept Therapeutics (Nasdaq:CORT) shares slipped 2.7% on Friday 31 July, closing at $115.17. That decline says far less about theBusinessthan the session before it. On 30 July, the day after second-quarter results landed, the stock climbed 27.3% on 4.5 million shares, roughly four times …
On 21 July, Danaher (NYSE:DHR) reported second-quarter net earnings of $870 million, against $555 million in the same period of 2025.GAAPDiluted Earnings per Sharewent from $0.77 to $1.23. On the face of it, that is a company compounding beautifully.
Dexcom (Nasdaq:DXCM) reported second-quarter 2026 results on 30 July with the combination its shareholders had stopped expecting: double-digit revenue growth, sharply better profitability, and a guidance raise that touched every line of the model. Revenue reached $1.308 billion, up 13% year over year as …
Alnylam (Nasdaq:ALNY) reported second-quarter 2026 results on 30 July, filed with the SEC as Exhibit 99.1 to an 8-K that day. The stock closed the session at $205.48, down 28.31% from the prior close of $286.62, onVolumeof 9.75 million shares, roughly seven times the …
Amgen (Nasdaq:AMGN) ended at $385.16, a little under 2% below the record close of $393.10 it set on 28 July, according to aggregated market data data. That 28 July session was the year's most violent: shares leapt roughly 4.5%, though vendors put the figure …
Pharmaceuticals (Nasdaq:ARWR). Arrowhead's transformation from a licensing shop into a commercial company has a date on it: when the FDA approved REDEMPLO (plozasiran) as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome. It is dosed as a subcutaneous injection …
Ascendis Pharma (Nasdaq:ASND) closed at $243.91 at last closing, down $7.16, or 2.85%, on the day. That single session sits inside a longer fade: the American depositary shares have given back roughly 12% since closing at $277.18 on 8 July, and now trade nearer …
Axsome Therapeutics (Nasdaq:AXSM) closed at $217.99 at last closing, down $16.65 or 7.10% on the session, according to aggregated market data. The drop more than erased the prior day's 3.17% gain and capped a week in which the stock fell from $241.00 on 24 …
Please wait processing your request...